Juvenile diabetes, now more commonly called type 1 diabetes, is a condition where the immune system destroys the cells in the pancreas that produce insulin. Without insulin, the body can’t move sugar from the bloodstream into cells for energy. About 1.8 million people under age 20 are living with type 1 diabetes worldwide, and roughly 164,000 children under 15 are diagnosed each year. While it’s called “juvenile” diabetes because it often appears in childhood or adolescence, it can develop at any age.
What Happens Inside the Body
Type 1 diabetes is an autoimmune disease. The immune system, which normally fights infections, mistakenly targets the insulin-producing beta cells in the pancreas. Specific white blood cells called CD8 T cells latch directly onto beta cells and kill them using toxic molecules. Meanwhile, CD4 T cells coordinate the attack by activating other immune players, including a type of inflammatory cell called an M1 macrophage. These macrophages release chemicals that are directly toxic to beta cells and create a destructive feedback loop: the more beta cells die, the more inflammation builds, and the more beta cells are destroyed.
By the time symptoms appear, the immune system has already wiped out a significant portion of the pancreas’s insulin-producing capacity. The process can take months or even years before enough beta cells are gone to cause noticeable problems, but the final decline into symptoms often feels sudden.
Why Some Children Develop It
The risk of type 1 diabetes comes from a combination of genetics and environmental triggers. The strongest genetic link involves specific immune system genes called HLA-DR and HLA-DQ, which influence how the body distinguishes its own cells from invaders. Certain versions of these genes make the immune system more likely to misidentify beta cells as threats. But genes alone aren’t enough. Identical twins share the same DNA, yet when one twin has type 1 diabetes, the other develops it only about 30 to 50 percent of the time.
Environmental factors appear to pull the trigger in genetically susceptible people. Viral infections are the most studied culprit. Changes in gut bacteria have also been linked to the disease. Alterations in the gut’s microbial balance can weaken the intestinal lining and disrupt immune tolerance, potentially nudging the immune system toward attacking the body’s own tissues. Pesticide exposure is another environmental factor researchers have flagged, though the exact mechanisms are still being studied.
Recognizing the Symptoms
The signs of type 1 diabetes in children typically develop quickly, over a matter of weeks. The classic symptoms are:
- Increased thirst and frequent urination: Without insulin, sugar accumulates in the blood. The kidneys work overtime to filter it out, pulling extra water along with it. A toilet-trained child who suddenly starts wetting the bed is a common early red flag.
- Extreme hunger with weight loss: The body can’t use sugar for fuel, so it starts breaking down fat and muscle instead. Children may eat constantly yet still lose weight.
- Fatigue and irritability: Cells starved of their primary energy source leave children feeling exhausted and out of sorts.
Diabetic Ketoacidosis: The Emergency to Know About
When type 1 diabetes goes unrecognized, the body shifts to burning fat for energy at a dangerous rate. This produces acidic byproducts called ketones that build up in the blood, leading to a life-threatening condition called diabetic ketoacidosis, or DKA. It’s often the event that leads to a child’s initial diagnosis.
Signs of DKA include nausea, vomiting, abdominal pain, rapid deep breathing, and a fruity smell on the breath caused by the body trying to expel acetone through the lungs. Children in DKA are typically visibly dehydrated and may appear thin. This is a medical emergency that requires hospital treatment with IV fluids and carefully managed insulin. One of the serious risks in children is brain swelling, which is why treatment follows a specific, cautious protocol rather than aggressive correction.
How Type 1 Diabetes Is Diagnosed
Diagnosis is straightforward once suspected. A random blood sugar reading of 200 mg/dL or higher in someone with symptoms points to diabetes. A fasting blood sugar of 126 mg/dL or above, or an A1C of 6.5 percent or higher, confirms it. The A1C reflects average blood sugar over roughly three months. To distinguish type 1 from type 2 diabetes, doctors test for autoantibodies, which are immune proteins that signal the body is attacking its own beta cells.
Living With Insulin Therapy
People with type 1 diabetes need insulin every day for the rest of their lives. The goal is to mimic what a healthy pancreas does naturally: provide a steady baseline of insulin throughout the day and release quick bursts at mealtimes.
Most treatment plans use two types of insulin. Long-acting insulin, which takes about two hours to start working and lasts up to 24 hours without a sharp peak, covers the body’s baseline needs. Rapid-acting insulin kicks in within 15 minutes, peaks at about one hour, and lasts two to four hours. It’s taken before meals to handle incoming carbohydrates. This combination, called multiple daily injections, requires four or more shots per day plus frequent blood sugar checks.
Insulin pumps offer an alternative. These small devices attach to the body and deliver a continuous trickle of rapid-acting insulin through a tiny tube under the skin. The user programs extra doses at mealtimes. The newest generation of pumps goes further by pairing with a continuous glucose monitor, a small sensor worn on the skin that reads blood sugar levels every few minutes and sends the data wirelessly. In automated insulin delivery systems, the pump and monitor talk to each other: the system reads the glucose level and adjusts insulin delivery automatically, increasing it when sugar is rising and decreasing or suspending it when sugar is dropping.
How Well Automated Systems Work
Clinical trials show these automated systems keep blood sugar in the target range significantly more than manual injections. The latest generation of hybrid closed-loop systems keeps adults in range about 73 to 75 percent of the time and adolescents about 72 to 73 percent. For younger children, the numbers are slightly lower, around 67 to 68 percent, but still represent a meaningful improvement over traditional injections. These systems are called “hybrid” because they still require users to enter carbohydrate counts at meals and occasionally approve correction doses. A fully automatic, no-input system doesn’t exist yet for everyday use.
Two large meta-analyses found automated delivery to be the most effective treatment strategy for keeping blood sugar in target range. Importantly, it achieves better control without increasing episodes of dangerously low blood sugar, which has historically been the tradeoff with tighter management.
Delaying Onset in High-Risk Children
For the first time, there is a medication that can delay the progression of type 1 diabetes in people identified as high-risk before they develop full-blown disease. Teplizumab, approved for adults and children aged 8 and older, targets a specific type of immune cell to slow the attack on beta cells. It’s currently limited to relatives of people with type 1 diabetes who have at least two types of autoantibodies and early signs of abnormal blood sugar but haven’t yet progressed to needing insulin.
In a pivotal trial of 76 participants, a single 14-day course of the medication delayed the onset of clinical diabetes by about two years compared to placebo. The median time to diagnosis was 48.4 months in the treatment group versus 24.4 months in the placebo group. In longer follow-up averaging about 6.5 years, half of those treated remained diabetes-free, compared to just 22 percent of the placebo group. A larger trial of 328 children and adolescents showed the drug preserved the pancreas’s remaining insulin-producing ability significantly better than placebo over 78 weeks.
This doesn’t prevent type 1 diabetes permanently, but the extra years without the disease are clinically meaningful, especially for young children. Every year of delayed onset is a year without the burden of daily insulin management during critical developmental stages.
The Scale of Type 1 Diabetes Today
An estimated 9.5 million people worldwide are living with type 1 diabetes as of 2025, up 13 percent from 8.4 million in 2021. Of those, about 1 million are children under 15 and 800,000 are teenagers between 15 and 19. Roughly 513,000 new cases are diagnosed each year across all ages, with the global incidence rising by about 2.4 percent annually. The reasons for this increase are not fully understood, but the pace of growth points to environmental factors playing a larger role over time, since genetic changes in a population don’t happen that fast.